# Absci Eyes December Hair-Loss Data, Reaffirms Mid-2027 Endometriosis Trial Target

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/55897
Published: 2026-11-12T20:59:33.000Z
Updated: 2026-11-12T20:59:33.000Z
Section: Business

> The company expects interim 13-week proof-of-concept findings for ABS-201 in December, followed by full 26-week data in early 2027.

Absci expects December interim findings from its experimental hair-loss antibody ABS-201, an early proof-of-concept milestone for pattern hair loss ahead of full 26-week data expected in early 2027.

The interim readout will cover 13 weeks of the Phase 1/2a HEADLINE study. The trial is randomized, double-blind and placebo-controlled. Its primary endpoints are safety and tolerability; secondary measures include hair count, width and pigmentation in target areas. Participants with pattern hair loss continued receiving doses in the multiple ascending dose portion of the study. The Nov. 12 business update included no hair-growth efficacy results.

Earlier HEADLINE findings covered safety and pharmacokinetics, or how a drug moves through the body, in 32 healthy adults who received single doses across four cohorts. Blinded interim safety data indicated the study drug was well tolerated, with no serious adverse events by the June 8 cutoff. Those findings were not evidence of hair-growth efficacy.

Absci also maintained a mid-2027 target to begin STORYLINE, its Phase 2 trial for endometriosis. The company’s August forecast called for a fourth-quarter 2026 start; a September update moved the target to mid-2027. The planned timeline remains subject to finalizing the protocol and receiving regulatory clearance.

STORYLINE is planned as a randomized, double-blind, placebo-controlled trial of ABS-201 in patients with surgically diagnosed endometriosis and moderate to severe endometriosis-associated pain. Absci plans to enroll approximately 150 patients across approximately 10 or more countries. Planned endpoints include reductions in dysmenorrhea, or painful menstruation, and non-menstrual pelvic pain.

The study is expected to use two or three dose levels, with the number to be confirmed after review of HEADLINE data. Absci’s next stated milestone for HEADLINE is the December interim readout; full 26-week data are expected in early 2027.